We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 0.37% | 219.72 | 205.00 | 224.00 | 221.53 | 217.00 | 218.00 | 758,529 | 01:00:00 |
By Colin Kellaher
Shares of Sage Therapeutics tumbled more than 45% in premarket trading Monday after the U.S. Food and Drug Administration rejected a key use for the biopharmaceutical company's depression drug with partner Biogen.
Sage and Biogen were seeking FDA approval of Zurzuvae, a fast-acting depression drug, for major depressive disorder, or MDD, and postpartum depression.
The agency late Friday gave a green light to Zurzuvae in postpartum depression but declined to approve the drug in the much larger indication of MDD, saying more studies were needed.
Biogen and Sage, both based in Cambridge, Mass., late Friday said they were reviewing their next steps for Zurzuvae in MDD, and Sage on Monday said it is evaluating steps to extend its cash runway, including a pipeline prioritization and a workforce reorganization.
Sage shares, which closed Friday at $36.10, were recently down nearly 47% to $19.24 in premarket trading, while shares of Biogen slipped 3% to $261.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 07, 2023 08:03 ET (12:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions